Overview

Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma

Status:
Active, not recruiting

Trial end date:
2023-09-30

Target enrollment:

Participant gender:

Summary

Given the established role of high dose cytarabine (HiDAC) combined with rituximab, along with recent data showing the encouraging efficacy of bendamustine, the investigators seek to integrate the synergistic effects of these medicines in alternating cycles as induction therapy prior to autologous stem cell transplant (ASCT). Based on prior experience with bendamustine and rituximab (BR) based induction therapy, the investigators seek to evaluate the efficacy and safety of stem cell mobilization in this pilot study

Phase:

Phase 1

Details

Lead Sponsor:

Washington University School of Medicine

Treatments:

Bendamustine Hydrochloride
Cytarabine
Rituximab